Latest News

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Elimination of HIV data protections and surveillance capacity undermines disease tracking and outbreak response capability.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

Insurance companies deploy AI algorithms for automated prior authorization denials, restricting patient access to prescribed treatments.

Reflection on advocacy values and health equity commitment during political transitions.

World AIDS Day reflection on ending the HIV epidemic: challenges and opportunities.

Bipartisan HCV elimination legislation analysis and critical legislative window.

Pugh reflects on 340B policy and patient advocacy in ensuring equitable medication access.

Call to action for community input on federal health policy initiatives.

Federal policy failures on copay accumulator programs restrict patient assistance benefits.

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

Gamification as innovative approach to HIV prevention education for youth.

Systemic barriers preventing HCV-infected people from accessing available cure.

ADA conflicts with state prescription drug affordability board operations.